Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-20
2009-10-20
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07605177
ABSTRACT:
This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.
REFERENCES:
patent: 4444879 (1984-04-01), Foster et al.
patent: 4511390 (1985-04-01), Kauer et al.
patent: 4699875 (1987-10-01), Appel et al.
patent: 4783524 (1988-11-01), Larsen et al.
patent: 4906614 (1990-03-01), Giertz et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5089406 (1992-02-01), Williams et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5114840 (1992-05-01), Tryggvason et al.
patent: 5149657 (1992-09-01), Maugh et al.
patent: 5243038 (1993-09-01), Ferrari et al.
patent: 5273961 (1993-12-01), Clark et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5451660 (1995-09-01), Builder et al.
patent: 5496712 (1996-03-01), Cappello et al.
patent: 5635604 (1997-06-01), Dalboge et al.
patent: 5639729 (1997-06-01), Goldstein et al.
patent: 5648335 (1997-07-01), Lewis et al.
patent: 5670616 (1997-09-01), Weber
patent: 5679552 (1997-10-01), Dalboge et al.
patent: 5686423 (1997-11-01), Wang et al.
patent: 5691169 (1997-11-01), Dalboge et al.
patent: 5703045 (1997-12-01), Lewis et al.
patent: 5710252 (1998-01-01), Weber et al.
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 5750376 (1998-05-01), Weiss et al.
patent: 5801045 (1998-09-01), Weber et al.
patent: 5804550 (1998-09-01), Bourguignon et al.
patent: 5804563 (1998-09-01), Still et al.
patent: 5861373 (1999-01-01), Gluckman et al.
patent: 5965531 (1999-10-01), Webster et al.
patent: 6054579 (2000-04-01), Harriman
patent: 6187906 (2001-02-01), Gluckman et al.
patent: 6294585 (2001-09-01), Brown
patent: 6342585 (2002-01-01), Grossmann
patent: 6365573 (2002-04-01), Gluckman et al.
patent: 6444657 (2002-09-01), Slusher et al.
patent: 2001/0018199 (2001-08-01), Dalboge et al.
patent: 2002/0013277 (2002-01-01), Gluckman et al.
patent: 2002/0035066 (2002-03-01), Gluckman et al.
patent: 2002/0115594 (2002-08-01), Bourguignon
patent: 2002/0177239 (2002-11-01), Thomas et al.
patent: 2003/0027755 (2003-02-01), Guan et al.
patent: 2003/0211990 (2003-11-01), Sieg et al.
patent: 86850417.6 (1986-12-01), None
patent: 227619 (1987-01-01), None
patent: 0 289 314 (1988-02-01), None
patent: 289314 (1988-02-01), None
patent: 88303855.6 (1988-04-01), None
patent: 8850306.7 (1988-09-01), None
patent: 308386 (1989-03-01), None
patent: 0366 638 (1990-05-01), None
patent: 366638 (1990-05-01), None
patent: 0 357 240 (1993-01-01), None
patent: 357240 (1993-01-01), None
patent: 1043027 (2000-11-01), None
patent: 1043027 (2000-11-01), None
patent: 2 707 170 (1995-01-01), None
patent: 270717 (1995-01-01), None
patent: WO 88/03533 (1988-05-01), None
patent: WO 88/08848 (1988-11-01), None
patent: WO 88/09171 (1988-12-01), None
patent: WO 89/01343 (1989-02-01), None
patent: WO 89/05822 (1989-06-01), None
patent: WO 90/05177 (1990-05-01), None
patent: WO 92/09695 (1992-06-01), None
patent: WO 93/02695 (1993-02-01), None
patent: WO93/08826 (1993-05-01), None
patent: WO 93/08826 (1993-05-01), None
patent: WO 93/08828 (1993-05-01), None
patent: WO 93/10806 (1993-06-01), None
patent: WO 93/20836 (1993-10-01), None
patent: WO 93/21216 (1993-10-01), None
patent: WO 94/23754 (1994-10-01), None
patent: WO 94/26301 (1994-11-01), None
patent: PCT/NZ 94/00143 (1994-12-01), None
patent: WO 94/00143 (1994-12-01), None
patent: WO 95/13823 (1995-05-01), None
patent: WO 95/17204 (1995-06-01), None
patent: WO 97/17090 (1997-05-01), None
patent: WO 97/39032 (1997-10-01), None
patent: WO 97/47735 (1997-12-01), None
patent: WO 98/14202 (1998-04-01), None
patent: WO 98/52620 (1998-11-01), None
patent: WO 99/08702 (1999-02-01), None
patent: WO 99/15192 (1999-04-01), None
patent: WO 99 15192 (1999-04-01), None
patent: WO 99/39210 (1999-08-01), None
patent: WO 99/65509 (1999-12-01), None
patent: WO 00/13650 (2000-03-01), None
patent: WO 02/16408 (2002-02-01), None
patent: WO 02/094856 (2002-11-01), None
Anthony J. Williams, et al., “Characterization of a New Rat Model of Penetrating Ballistic Brain Injury”, Jnl. of Neurotrauma, MD, vol. 22, No. 2, 2005, pp. 314-332.
Jed a. Hartings, et al, “Occurrence of nonconclusive seizures, periodic epileptiform discharges, and intermittent rhythmic delta activity in ratFocal ischemia”, Experimental Neurology 179 (2003) pp. 139-149.
P.M. Vespa, MD, et al., “Acute seizures after intracerebral hemorrhage—A factor in progressive midline shift and outcome”, Division of Neurosurgery, Department of Neurology, UCLA Stroke Center, Jan. 20, 2003, pp. 1441-1446.
Michael Privitera, et al., “EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness”, Department of Neurology, University of Cincinnati Medical Center, Feb. 16, 1994, pp. 155-166.
Paul M. Vespa, M.D., et al., “Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring”, J. Neurosurg vol. 91:750-760, 1999.
Lu, X.-C, A Glypromate Analog, NNZ-2566, is Neuroprotective in Rats Subjected to Penetrating Ballistic-Like Brain Injury (PBBI), Div. Psychiatry and Neuroscience, Walter Reed.
Army Institute of Research, Silver Spring, MD, 20910, Journal of Neurotrauma, vol. 10 (#22), p. 1255, Oct. 2005.
Notification of Transmittal of The International Search Report and The Written Opinion of the International Searching Authority; International Bureau dated Apr. 24, 2007 in International Application No. PCT/US06/19909.
Lucas, M.D., D. R., et. al., “The Toxic Effect of SodiumL-Glutamate on the Inner Layers of the Retina”,Archives of Opthamology, 58, 1957, pp. 198-204.
Curtis, David R., et. al., “Amino Acid Transmitters in the Mammalian Central Nervous System”,Ergebnisse der Physiologie, 69, 1974, pp. 97-188.
Bauer, Carl-Axel, “Active Centers of α-Chymotrypsin and ofStreptomyces griseusProteases 1 and 3,” Department of Biochemistry, University of Lund, Nov. 5, 1979, pp. 565-570.
Carone, R.A. et al., “Differences Between in vitro and in vivo Degradation of LHRH by Rat Brain and Other Organs,”American Journal of Physiology, 253, 1987, E317-E321.
Szabo, Laszlo, et. al., “The Bovine Insulin-like Growth Factor (IGF) Binding Protein Purified from Conditioned Medium Requires the N-Terminal Tripeptide in IGF-1 for Binding,”Biochemical and Biophysical Research Communications, vol. 151, No. 1, Feb. 29, 1988, pp. 207-214.
Shepard, M.D., Gordon M.,“Neurotransmitters and Neuromodulators,” Neurobiology, 2nd edition, 1988, pp. 145-176.
Sakaki, Atsushi, et al., “Multiple Forms of Immunoreative Growth Hormone-Releasing Hormone in Human Plasma, Hypothalamus, and Tumor Tissues,” Journal of Clinical Endocrinology and Metabolism, vol. 68, No. 1, 1989, pp. 180-185.
Bourguignon, Jean-Pierre, et. al., “Pulsatile Release of Gonadortropin-Releasing Hormone from Hypothalamic Explants is Restrained by Blockade ofN-Methyl-D,L-Aspartate Receptors,” Endocrinology, vol. 125, No. 2, 1989, pp. 1090-1096.
Sara, Vicki R., et. al., “Identification of Gly-Pro-Glu (GPE), the Aminoterminal Tripeptide of Insulin-like Growth Factor 1 Which is Truncated in Brain, as a Novel Neuroactive Peptide,” Biochemical and Biophysical Research Communications, Vol. 165, No. 2, Dec. 15, 1989, pp. 766-771.
Donoso, Alfredo O., et. al., “Glutamate Receptors of the Non-N-Methyl-D-Aspartic Acid Type Mediate the Increase in Luteinizing Hormone-Releasing Hormone Release by Excitatory Amino Acids in Vitro”,Endocrinology, vol. 126, No. 1, 1990, pp. 414-420.
Bourguignon, Jean-Pierre, et. al., “Mat
Anand Ashmit Kumar
Brimble Margaret Anne
Dragunow Michael
Gluckman Peter David
Guan Jian
Anderson Rebecca L
Borson D. Benjamin
Neuren Pharmaceuticals Limited
LandOfFree
Effects of glycyl-2 methyl prolyl glutamate on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Effects of glycyl-2 methyl prolyl glutamate on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Effects of glycyl-2 methyl prolyl glutamate on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4057037